Sinil Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	80,564	89,440	89,135	80,007	61,754
Other Revenue	-0	-0	-	-0	-
Revenue	80,564	89,440	89,135	80,007	61,754
Revenue Growth (YoY)	-9.93%	0.34%	11.41%	29.56%	0.52%
Cost of Revenue	47,127	48,774	51,565	44,362	37,313
Gross Profit	33,437	40,666	37,570	35,645	24,441
Selling, General & Admin	22,636	21,238	19,491	17,623	15,574
Research & Development	2,694	2,802	2,979	3,264	194.52
Other Operating Expenses	422.17	347.33	355.82	378.68	374.75
Operating Expenses	26,052	25,445	23,579	21,989	16,459
Operating Income	7,386	15,222	13,991	13,656	7,982
Interest Expense	-19.71	-26.97	-26.13	-6.05	-9.72
Interest & Investment Income	1,149	1,074	849.37	352.84	184.48
Currency Exchange Gain (Loss)	-21.61	43.68	-59.59	90.91	26.14
Other Non Operating Income (Expenses)	19.04	217.24	1,379	899.91	14.64
EBT Excluding Unusual Items	8,512	16,530	16,134	14,994	8,197
Gain (Loss) on Sale of Investments	1.34	-26.81	-532.61	-478.44	115.48
Gain (Loss) on Sale of Assets	-24.33	3.72	-641.55	221.3	14
Asset Writedown	108.28	31	-7	-92.08	14.5
Pretax Income	8,597	16,538	14,953	14,645	8,341
Income Tax Expense	1,067	2,237	1,312	2,488	1,663
Net Income	7,531	14,301	13,641	12,157	6,679
Net Income to Common	7,531	14,301	13,641	12,157	6,679
Net Income Growth	-47.34%	4.83%	12.21%	82.02%	-11.47%
Shares Outstanding (Basic)	-	12	12	11	11
Shares Outstanding (Diluted)	-	12	12	11	11
Shares Change (YoY)	-	-0.02%	3.94%	-1.05%	-0.11%
EPS (Basic)	-	1237.13	1179.82	1092.89	594.11
EPS (Diluted)	-	1237.13	1179.82	1092.89	594.11
EPS Growth	-	4.86%	7.95%	83.95%	-11.37%
Free Cash Flow	8,444	12,327	1,551	3,336	7,820
Free Cash Flow Per Share	-	1066.39	134.13	299.94	695.63
Gross Margin	41.50%	45.47%	42.15%	44.55%	39.58%
Operating Margin	9.17%	17.02%	15.70%	17.07%	12.93%
Profit Margin	9.35%	15.99%	15.30%	15.20%	10.81%
Free Cash Flow Margin	10.48%	13.78%	1.74%	4.17%	12.66%
EBITDA	13,377	20,828	19,353	18,088	12,518
EBITDA Margin	16.60%	23.29%	21.71%	22.61%	20.27%
D&A For EBITDA	5,991	5,607	5,361	4,432	4,536
EBIT	7,386	15,222	13,991	13,656	7,982
EBIT Margin	9.17%	17.02%	15.70%	17.07%	12.93%
Effective Tax Rate	12.40%	13.53%	8.77%	16.99%	19.93%
Advertising Expenses	622.21	980.01	1,059	762.13	157.25

Source: S&P Global Market Intelligence. Standard template. Financial Sources.